Johnson & Johnson, U.S. government expand pact to support next phase of COVID-19 vaccine R&D
(Reuters) - Johnson & Johnson and the U.S.
COVID-19 vaccine R&D" src="https://images.firstpost.com/wp-content/uploads/reuters/11-2020/15/2020-11-14T174541Z_1_LYNXMPEGAD0ET_RTROPTP_2_HEALTH-CORONAVIRUS-VACCINE.jpg" alt="Johnson Johnson US government expand pact to support next phase of COVID19 vaccine RD" width="300" height="225" />
(Reuters) - Johnson & Johnson and the U.S. Department of Health and Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development, the company said on Saturday.
Under the agreement the company will commit approximately $604 million and the HHS Department's Biomedical Advanced Research and Development Authority will commit about $454 million to support the Phase 3 ENSEMBLE trial evaluating Janssen's investigational COVID-19 vaccine candidate as a single dose in up to 60,000 volunteers worldwide, the company said in a statement
(Reporting by Sabahatjahan Contractor in Bengaluru; Editing by Matthew Lewis)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
By Johannes Hellstrom, Bart H.
By Medha Singh and Shivani Kumaresan (Reuters) - Wall Street gained on Friday as Disney and Cisco's upbeat results brought the focus back to corporate earnings at the end of a volatile trading week that saw record surges in coronavirus cases and increased hopes of a working vaccine.
By Sumita Layek (Reuters) - Gold gained as much as 1.1% on Friday as rising global coronavirus infections re-ignited concerns about the economic toll from the pandemic, while scepticism over the reach of a potential COVID-19 vaccine further boosted the safe-haven metal. Spot gold rose 0.8% to $1,890.81 per ounce by 11:33 a.m